

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DKT. NO.  
BAYER 15ASERIAL NO.  
09/889,227INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

## APPLICANT

Bernd Riedl et al.

## FILING DATE

January 8, 2002

## GROUP

1625

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
------------------	-----------------	------	------	-------	----------	-------------

	AA	502,504	8/1/1893	Thoms		
	AB	1,742,156	2/31	Fritzky		
	AC	2,046,375	7/36	Goldstein et al.		
	AD	2,093,265	9/36	Coffby et al.		
	AE	2,288,422	6/42	Rohm		
	AF	2,649,476	8/18/53	Martin		
	AG	2,683,082	7/54	Hill et al.		
	AH	2,722,544	11/1/55	Martin		
	AI	2,745,874	5/56	Schetty et al.		
	AJ	2,781,330	2/57	Downey		
	AK	2,797,214	6/25/57	Werner Bossard		
	AL	2,867,659	1/59	Model et al.		
	AM	2,877,268	3/59	Applegate et al.		
	AN	2,960,488	11/60	Tamblyn et al.		
	AO	2,973,386	2/61	Weldon		
	AP	3,151,023	9/64	Martin		
	AQ	3,200,035	8/65	Martin et al.		
	AR	3,230,141	1/66	Frick et al.		
	AS	3,424,760	01/28/69	Helsley et al.		
	AT	3,424,761	01/28/69	Helsley et al.		
	AU	3,424,762	01/28/69	Helsley et al.		
	AV	3,547,940	12/15/70	Brantley		
	AW	3,646,059	02/29/72	Brantley		
	AX	3,689,550	9/72	Schellenbaum et al.		
	AY	3,743,498	7/3/73	Brantley		
	AZ	3,754,887	08/28/73	Brantley		
	BA	3,823,161	07/09/74	Lesser		
	BB	3,828,001	8/74	Broad et al.		
	BC	3,860,645	1/95	Nikawitz		
	BD	3,990,879	11/9/1976	Soper		
	BE	4,001,256	1/4/97	Callahan et al.		
	BF	4,009,847	3/1/77	Aldrich et al.		
	BG	4,042,372	8/16/1977	Harper		
	BH	4,062,861	12/13/77	Yukinaga et al.		
	BI	4,071,524	01/31/78	Banitt		
	BJ	4,111,680	09/05/78	Yukinaga et al.		

RECEIVED  
TECH CENTER 1600  
JUN 11 2002  
1600/2900

	<b>BK</b>	4,111,683	09/05/78	Singer			
	<b>BL</b>	4,116,671	09/26/78	Yukinaga et al.			
	<b>BM</b>	4,173,637	11/79	Nishiyama et al.			
	<b>BN</b>	4,173,638	11/79	Nishiyama et al.			
	<b>BO</b>	4,183,854	1/80	Crossley			
	<b>BP</b>	4,212,981	07/15/80	Yukinaga et al.			
	<b>BQ</b>	4,240,820	12/23/80	Dickore et al.			
	<b>BR</b>	4,405,644	9/20/83	Kabbe et al.			
	<b>BS</b>	4,410,697	10/18/83	Török et al.			
	<b>BT</b>	4,437,878	03/20/84	Acker et al.			
	<b>BU</b>	4,468,380	8/28/84	O'Doherty et al.			
	<b>BV</b>	4,473,579	9/25/84	Devries et al.			
	<b>BW</b>	4,511,571	4/85	Böger et al.			
	<b>BX</b>	4,514,571	04/30/85	Nakai et al.			
	<b>BY</b>	4,526,997	7/2/85	O'Doherty et al.			
	<b>BZ</b>	4,623,662	11/18/86	De Vries			
	<b>CA</b>	4,643,849	02/17/87	Hirai et al.			
	<b>CB</b>	4,740,520	4/88	Hallenbach et al.			
	<b>CC</b>	4,760,063	7/26/88	Hallenbach et al.			
	<b>CD</b>	4,808,588	02/28/89	King			
	<b>CE</b>	4,820,871	4/89	Kissener et al.			
	<b>CF</b>	4,863,924	9/89	Haga et al.			
	<b>CG</b>	4,983,605	1/91	Kondo et al.			
	<b>CH</b>	4,985,449	1/15/91	Haga et al.			
	<b>CI</b>	5,036,072	7/91	Nakajama et al.			
	<b>CJ</b>	5,059,614	10/22/91	Lepage et al.			
	<b>CK</b>	5,098,907	3/92	Kondo et al.			
	<b>CL</b>	5,130,331	07/14/92	Pascual			
	<b>CM</b>	5,162,360	11/10/92	Creswell et al.			
	<b>CN</b>	5,185,358	2/9/1993	Creswell			
	<b>CO</b>	5,312,820	5/17/94	Ashton et al.			
	<b>CP</b>	5,319,099	6/7/94	Kamata et al.			
	<b>CQ</b>	5,399,566	3/21/95	Katano et al.			
	<b>CR</b>	5,423,905	6/95	Fringeli			
	<b>CS</b>	5,429,918	7/4/1995	Seto et al.			
	<b>CT</b>	5,432,468	7/11/95	Moriyama et al.			
	<b>CU</b>	5,470,882	11/95	Dixon et al.			
	<b>CV</b>	5,500,424	3/19/96	Nagamine et al.			
	<b>CW</b>	5,508,288	04/16/96	Forbes et al.			
	<b>CX</b>	5,597,719	1/28/97	Freed et al.			
	<b>CY</b>	5,696,138	12/9/97	Olesen et al.			
	<b>CZ</b>	5,698,581	12/16/97	Kleemann et al.			
	<b>DA</b>	5,773,459	06/30/98	Tang et al.			
	<b>DB</b>	5,780,483	7/14/98	Widdowson et al.			
	<b>DC</b>	5,780,483	7/14/98	Widdowson et al.			
	<b>DD</b>	5,807,891	9/15/98	Bold et al.			

	<b>DE</b>	5,814,646	9/29/1998	Heinz			
	<b>DF</b>	5,886,044	3/23/99	Widdowson et al.			
	<b>DG</b>	5,891,895	4/6/99	Shiraishi et al.			
	<b>DH</b>	5,908,865	6/1/1999	Doi et al.			
	<b>DI</b>	5,965,573	10/12/99	Petrie et al.			
	<b>DJ</b>	6,004,965	12/21/99	Breu et al.			
	<b>DK</b>	6,005,008	12/21/99	Widdowson et al.			
	<b>DL</b>	6,020,345	2/1/00	Vacher et al.			
	<b>DM</b>	6,040,339	3/21/00	Yoshida et al.			
	<b>DN</b>	6,080,763	6/27/2000	Regan et al.			
	<b>DO</b>	6,093,742	7/25/00	Salituro et al.			
	<b>DP</b>	6,133,319	10/17/00	Widdowson			
	<b>DQ</b>	6,150,415	11/21/00	Hammock et al.			
	<b>DR</b>	6,174,901B1	1/16/01	Mantlo et al.			
	<b>DS</b>	6,178,399B1	1/23/01	Takebayashi et al.			
	<b>DT</b>	6,180,675B1	1/30/01	Widdowson et al.			
	<b>DU</b>	6,187,799B1	2/13/01	Wood et al.			
	<b>DV</b>	6,211,373B1	4/3/01	Widdowson et al.			
	<b>DW</b>	6,218,539B1	4/17/01	Widdowson et al.			
	<b>DX</b>	6,242,601B1	6/5/01	Breu et al.			
	<b>DY</b>	6,262,113B1	7/17/01	Widdowson et al.			
	<b>DZ</b>	6,271,261B1	8/7/01	Widdowson			
	<b>EA</b>	6,333,341B1	12/25/01	Mantlo et al.			
	<b>EB</b>	6,339,045B1	1/15/02	Kanno et al.			

#### FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	<b>EC</b>	90/02112	3/8/90	WO			
	<b>ED</b>	93/18028	09/16/93	WO			
	<b>EE</b>	93/24458	12/9/93	WO			
	<b>EF</b>	94/14801	07/07/94	WO			
	<b>EG</b>	94/22807	10/13/94	WO			
	<b>EH</b>	94/18170	08/18/94	WO			
	<b>EI</b>	94/25012	11/10/94	WO			
	<b>EJ</b>	95/02591	01/26/95	WO			
	<b>EK</b>	95/07922	03/23/95	WO			
	<b>EL</b>	95/13067	05/18/95	WO			
	<b>EM</b>	95/31451	11/23/95	WO			
	<b>EN</b>	95/33458	12/14/95	WO			
	<b>EO</b>	96/10559	4/11/96	WO			
	<b>EP</b>	96/25157 A1	8/22/96	WO			
	<b>EQ</b>	96/40673	12/19/96	WO			
	<b>ER</b>	96/40675 A1	12/19/96	WO			
	<b>ES</b>	97/17329	5/15/97	WO			

	ET	97/29743	8/21/97	WO				
	EU	97/30992	8/28/97	WO				
	EV	97/40028 A1	10/30/97	WO				
	EW	97/49400	12/31/97	WO				
	EX	97/49399	12/31/97	WO				
	EY	97/45400	12/4/97	WO				
	EZ	98/17267	4/30/98	WO				
	FA	98/22103	5/28/1998	WO				
	FB	98/22432	5/28/98	WO				
	FC	98/52558	11/26/98	WO				
	FD	98/52559	11/26/98	WO				
	FE	99/00357	1/7/99	WO				
	FF	99/00370	1/7/99	WO				
	FG	99/23091	5/14/99	WO				
	FH	99/24398	5/20/99	WO				
	FI	99/32106	7/1999	WO				
	FJ	99/32110	7/1/99	WO				
	FK	99/32111	7/1/1999	WO				
	FL	99/32436	7/1/99	WO				
	FM	99/32437	7/1/99	WO				
	FN	99/32455	7/1/1999	WO				
	FO	99/32463	7/1/99	WO				
	FP	99/33458	7/8/99	WO				
	FQ	99/40673	8/12/99	WO				
	FR	00/17175	3/30/2000	WO				
	FS	00/43366A1	01/20/2000	WO				
	FT	00/43384	7/27/2000	WO				
	FU	00/55139	9/21/2000	WO				
	FV	00/55152	9/21/2000	WO				
	FW	0016371A1	3/5/80	EP				
	FX	0 405 233	1/91	EP				
	FY	0116932	8/29/84	EP				
	FZ	242666	10/28/87	EP				
	GA	335156	03/11/89	EP				
	GB	371876	11/28/89	EP				
	GC	459887	05/28/91	EP				
	GD	676395	7/17/1996	EP				
	GE	0202538A1	11/26/86	EP				
	CF	860433A1	8/26/98	EP				
	GG	0 523 437	5/31	Germany				
	GH	0 511 468	10/30	Germany				
	GI	0 487 014	12/29	Germany				
	GJ	0 253 997	2/88	East Germany				
	GK	2436179A1	2/6/1975	DE				
	GL	2436179C2	2/6/75	DE				

	GM	25 01 648	7/24/75	DE				
	GN	35 40 377 A1	11/14/85	DE				
	GO	35 29 247 A1	8/20/85	DE				
	GP	3305866A1	02/19/83	DE				
	GQ	3 532 47	3/91	Japan				
	GR	8 031841	11/19/96	Japan				
	GS	44 2569	2/69	Japan				
	GT	10-306078	11/17/98	Japan				
	GU	50-149668	11/75	Japan				
	GV	50-76072	6/75	Japan				
	GW	50-77375	6/75	Japan				
	GX	51 063170	1/6/76	Japan				
	GY	51-80862	7/76	Japan				
	GZ	53 086033	7/29/78	Japan				
	HA	55 98152	7/80	Japan				
	HB	55-124763	9/80	Japan				
	HC	55-162772	12/80	Japan				
	HD	0 771 333	3/57	Great Britain				
	HE	0 828 231	10/56	Great Britain				
	HF	0 921 682	3/63	Great Britain				
	HG	1,590,870	06/10/81	Great Britain				
	HH	1 457 172	9/66	France				
	HI	2,146,707	10/12/95	Canada				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	HJ	Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryozo et al., November 15, 1982
	HK	Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981
	HL	Caplus 84:43857, Abstract JP 58021626, Maeda Ryozo et al., May 2, 1983
	HM	Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980
	HN	Abstract of EP 202,538
	HO	Abstract of DE 3305866 (EP equivalent 116,932)
	HP	Abstract of EP 116,932
	HQ	Abstract of EP 16,371
	HR	Abstract of EP 4931A equivalent 4,240,820)
	HS	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
	HT	Abstract WO 9822103, Hedge 28 May 1998
	HU	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742
	HV	Tarzia, G. et al., "Whythesis and anit-inflammatory properties of some pyrrolo(1H,3H)-[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
	HW	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
	HX	Audia, James E., et al., "Potent, Selective Tetraphdro-β-carboline Antagonists of the Serotonin 2B (5HT <sub>2B</sub> ) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.

	<b>HY</b>	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT <sub>2B</sub> Receptor Antagonist," March 17, 1995, pages 855-57.
	<b>HZ</b>	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. <sup>1</sup> A Generalised Monocyclic Rearrangement," 1967, 2005-07.
	<b>HZ</b>	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
	<b>IA</b>	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
	<b>IB</b>	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
	<b>IC</b>	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
	<b>ID</b>	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
	<b>IE</b>	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
	<b>IF</b>	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
	<b>IG</b>	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
	<b>IH</b>	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
	<b>II</b>	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
	<b>IJ</b>	G. Daum, et al., The ins and outs of Raf Kinases; TIBS 19, November 1994, pages 474-80.
	<b>IK</b>	Grant, A.M. et al.: "Hypotensive thiadiazoles" J. Med. Chem. (1972), 15(10), 1082-4.
	<b>IL</b>	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo'3,2-a'-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
	<b>IM</b>	Joseph T. Bruder and Imre Kovesdi, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression, May 17, 1996, pp. 198-404.
	<b>IN</b>	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), 339-50
	<b>IO</b>	Kubo, Hiroshi et al. "Herbicidal activity of 1,3,4-thiadiazole derivatives" J. Agr. Food Chem. (1970) , 18(1), 60-5
	<b>KP</b>	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
	<b>KQ</b>	
	<b>KR</b>	
	<b>KS</b>	
	<b>KT</b>	
	<b>KU</b>	
	<b>KV</b>	
	<b>KW</b>	
	<b>KX</b>	
	<b>KY</b>	
	<b>KZ</b>	
Examiner		Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.